CRIS goes live: activation brings bigger, better electronic hospital system
Dr. Scott Solomon, of the Hematology Branch, NHLBI, and nurse Laura Wisch, familiarize themselves with CRIS data input.
It's Friday evening, August 21, 2004. Normally all of the inpatients' medical orders are printed out at midnight; tonight, no orders are to be entered after 10. At midnight, the Clinical Center is turning off the electronic medical information system (MIS) it has used for 28 years. If all goes well, at 7:30 Saturday morning the staff will turn on the first part of a new, bigger, better electronic hospital information system-the core of the CC's new clinical research information system (better known as CRIS).
For seven weeks, from 7 a.m. until 11 p.m, staff have been training on the system. Inevitably, many have waited until the last minute.
When MIS went live for inpatient documentation in 1976, it did so one nursing unit at a time, starting with 5-West. Most institutions going from paper to electronic records come on one physical area or one function at a time. Because the CC is changing from one electronic system to another and can't maintain data in both systems, CRIS was to be introduced in a "big bang"turning the core hospital system on everywhere, all at once. When the original go-live date of July 30 was changed, the CRIS team turned on the subsystem for retrieving historic (not live) data to give users experience with part of the system.
Ultimately CRIS will include two dozen different systems around one clinical and one research hub. The part of CRIS scheduled to go live Saturday morning is the first part of the core hospital information system, focused on patient care. A week earlier, all the laboratory results and most clinical documentation from MIS were transferred to CRIS, so staff could see how they looked in the new system.
Clinical Informatics has set up a lounge for breaks, with a large-screen television and enough food to sustain dozens of people, some working through the night. One can sense the combined fatigue and high energy that come with difficult but important team deadlines. Close to 200 people (CC and NIH staff and contractors) have worked long hours for weeks to get the system ready. Many work into Friday nightsome until Saturday morning, many for more than 24 hours at a stretch. All day Friday and into the evening prescribers have been entering patients' current medical orders into the new system.
At 11:30 the overhead announcements begin all over Building 10: "The MIS system will be down in one half hour." Another message comes at 15 minutes before, then 5 before, then at midnight: "MIS is shutting down." On cue, technical staff and contractors begin connecting all the interfaces. Some of the staff catch a few winks in patient beds reserved for the occasion on the twelfth floor.
Friday night and Saturday morning they encounter two obscure software problems. Identifying the problems takes longer than solving them, but a CC employee finds a report about one on the Internet; nobody present has ever heard of it and the symptoms provide no clue to the problem (a bug in the operating system which, combined with troubleshooting other problems, creates totally unpredictable behavior).
Saturday at 6 a.m., a team of extremely tired technical and medical staff and contractors convene to decide whether CRIS should go live as scheduled. They delay for hours, with Dr. Steve Rosenfeld, the Clinical Center's chief information officer and associate director for clinical research information systems, periodically giving status reports to all staff. Finally, Rosenfeld calls together key parties and asks for recommendations. The decision: Postpone a full day, get things worked out as best we can and make the go-live Sunday morning.
This gives the exhausted team a chance to sleep, and all day Saturday people keep entering documentation and getting used to the system.
Sunday morning, August 23, 2004, CRIS goes live.
"There was a very strong feeling of NIH community during those few days," says Dr. Cliff Lane (NIAID), chair of the CRIS project steering committee. "I didn't see people losing their tempers or getting angry or frustrated. There was frustration with not getting the system in, but I think everyone bonded as an NIH community, because everyone knew how important this is, particularly to the safety and the care of the patients."
"Other than the fact that we were all exhausted, I don't think we lost anything by waiting till Sunday," says Rosenfeld. "And when we finally did go live everybody was rested. Since Sunday morning, the system has been up and running smoothly."
Not that there weren't problems, including a problem with printers-some not printing at all and some printing far too much. But the worst problems were in the outpatient pharmacy. Many new pharmacy options were built into CRIS, but they weren't completed by the go-live, so some people who hadn't had enough practice on the system were entering orders incorrectly and not getting feedback-still to be incorporated is a system of alerts about user errors. The pharmacy was extremely busy for well over a week.
"Walking through the hospital, you saw a lot of busyness in the nursing units, and a lot of people helping each other with the new system," says Rosenfeld. "The one place where CRIS had an unacceptable impact was in the outpatient pharmacy," where patients had to wait far too long. "We're still not back to where we were."
Problems were inevitable and there are details still to be worked out. But there have already been big gains. Reviewing patient data is almost a different experience, the improvement over MIS is so dramatic. The screen design is more efficient and user-friendly, and the system offers more decision support. The core system was repackaged to provide a standard clinical desktop with pull-down menus, icons, more easily read fonts, and other features familiar to computer users. As physician Peter Crompton, an NIH fellow, said after trying the new system, "A bad day with CRIS is better than a good day with MIS."
With MIS you could pull out data for one patient only. With CRIS, you can retrieve much more data. Looking at a list of all the patients under your care, you can see flags for orders or results you haven't reviewed yet, so you know at a glance what work you have to do. You can show trends in data, create customized patient lists (all inpatients, all consults, etc.), retrieve all the data on one patient in different views, and retrieve data across patients and across protocols.
Writing orders and retrieving data is easier and more logical now, says Lane. "With MIS, for example, let's say I wanted to order a drug. I'd have to go to the master screen, go to the pharmacy screen, go to an alphabet screen, find the drug, go to the drug, and then (depending upon the drug) probably go through another three to seven screens. With CRIS I can type in the first three letters of the drug I want and that order will appear to me immediately. Depending upon how much I want to change it, two or three screens and I'm done."
"I think we did a good job," says Rosenfeld. "We were as prepared as we could be. And I have to say, everybody really rose to the occasion-from the nursing department to the doctors, from the lab technologists and diagnostic radiology to the pharmacists. We were ready to have help available all over the place, but it was still a huge inconvenience to people, and everybody accepted it and dealt with it extremely well."
"The response of the NIH patient care community to CRIS activation was extraordinary," says Clinical Center Director John I. Gallin. "I thank the entire CRIS team for their special work and I am delighted that the initial phase of activation has been completed successfully. In the next few years the system's clinical research component will mature with the development of a new data warehouse to store and merge clinical and research information. We look forward to CRIS's continued development."
- by Pat McNees
Lecture on insulin resistance to be held November 3
Dr. Gerald M. Reaven will deliver the Astute Clinician Lecture, "Insulin Resistance and Metabolic Syndromes: Different Names, Different Concepts, Different Goals," on Wednesday, November 3, at 3 p.m. in Masur Auditorium.
Dr. Gerard Reaven
Reaven, a professor of medicine at Stanford University School of Medicine's Division of Cardiovascular Medicine, has been on Stanford's faculty for more than 40 years. His research has advanced the understanding of diabetes and related disorders, including insulin resistance.
Insulin resistance is marked by high levels of insulin in the blood. Although this tends to keep blood sugar levels down, it can eventually lead to type II diabetes; the pancreas becomes overtaxed and cannot continue to produce such high insulin levels. It also leads to other medical conditions, including heart disease.
Abnormalities associated with insulin resistance were first recognized in the late 1980s. Since then much new information has come forth about insulin resistance and disease. This has led to two approaches in thinking about the condition. One approach has been to recognize that the abnormalities associated with insulin resistance have broadened and to change the way physicians view the clinical syndromes associated with the condition.
The second approach is to establish criteria to diagnose this metabolic syndrome as a way to identify those at risk for developing heart disease. The lecture will explore the implications of these two approaches.
Reaven earned his MD and completed his internship at the University of Chicago. After a residency in internal medicine at the University of Michigan in 1959, he went to Stanford, where he has been since. He served as instructor (1960), associate professor (1965), professor (1970), head of the division of endocrinology and metabolic diseases (1974-1977), head of the division of gerontology (1977-1990) and director of Stanford's General Clinical Research Center, which he established (1977-1990). A longtime professor of medicine at Stanford, he has been professor emeritus since 1995.
He has published more than 500 articles in scientific journals and numerous textbook chapters and other scholarly works and has received the highest awards for research from the American Diabetes Association, the British Diabetes Association, and the European Association for the Study of Diabetes.
The Astute Clinician Lecture was established through a gift from Haruko and Dr. Robert W. Miller. Each year it honors a U.S. scientist who has observed an unusual clinical occurrence and, by investigating it, has opened an important new avenue of research.
The Astute Clinician Lecture is an NIH Director's Wednesday Afternoon Lecture Series event. It is hosted by the Clinical Center. For information and accommodations, contact Hilda Madine, 301-594-5595.
Clinical Center and NIAID lead West Nile Virus treatment trial
The Clinical Center and NIAID have responded to the West Nile Virus (WNV) epidemic that has swept across the nation by developing a multicenter study seeking to find safe treatments for encephalitis, one of the most severe symptoms of WNV. Researchers are testing the safety and preliminary effectiveness of using WNV anti-bodies to treat people in whom the virus has reached, or threatens to reach, the brain.
"The high death rate seen among
persons with WNV encephalitis-
swelling of the brain-and the longterm
consequences of the disease
among survivors provide impetus for
this research," said study chair Dr.
Amy Agrawal, of the Clinical
Center's Critical Care Medicine
WNV is a mosquito-borne virus
that can cause encephalitis, spinal
cord damage and other serious problems.
Only 1 to 3 percent of human
infections cause this clinically important
disease, but that 1 to 3 percent
can have devastating and long-term
consequences. Elderly and immunosuppressed
individuals are those most
likely to experience the virus's devastating
complications. In 2003, more
than 9,000 cases in the U.S. were
reported and in 2004 virtually every
state reported multiple cases of WNV.
According to Agrawal, events in a
WNV outbreak in Israel in 2000 provided
the rationale for this specific
trial. One Israeli patient had low antibody
levels, developed WNV-induced
encephalitis and per routine medical
practice was given intravenous
immunoglobulin (IVIG). Her recovery
was dramatic. This IVIG preparation
was then analyzed to see if it had any
WNV antibodies; the preparation had
very high concentrations, by contrast
with American IVIG, which contained
"This is because WNV has circulated
in Israel since the 1940s and
their population has a high level of
antibodies to the viral infection,"
explained Agrawal. "This long-term
exposure creates immunity to WNV
in a large proportion of the population.
When you pool the blood from
multiple donors and formulate the
IVIG, it will then have many antibodies
directed against West Nile virus."
By contrast, only a small percentage
of the U.S. population has antibodies
against West Nile virus.
Currently, clinicians have few
treatment options aside from providing
supportive care for treating
people sick with severe WNV symptoms.
If the Israeli IVIG compound
being tested in this trial is proven
safe as a treatment for these complications,
researchers will have a better
understanding of WNV, develop
treatments for it and possibly prevent
it, Agrawal said. The compound is
pooled antibodies obtained from
Israeli donors with high levels of the
"To have any effect this IVIG
agent needs to be given early,"
Agrawal explained. Animal models
have shown that the Israeli IVIG
product provides therapeutic benefit
if given promptly after infection.
Alpha interferon is being assessed by
another group of investigators,
although animal data are not as
promising with alpha interferon as
with the IVIG.
This protocol represents an intramural/
extramural NIH alliance. Dr.
Richard Whitely and Dr. John Gnann,
of the University of Alabama at
Birmingham, who lead the NIAIDfunded
Collaborative Antiviral Study
Group, have worked closely with
Agrawal and with Dr. Walla Dempsey
(NIAID) to develop this national,
multicenter project. More than 60
sites nationally, in addition to the
Clinical Center, are now prepared to
study West Nile patients on this protocol.
Agrawal believes this study could
serve as a prototype for researching
outbreak-type diseases and bioterrorism-
type events. "The challenges
posed by trying to 'chase the outbreak'
are complicated by delays as
institutional review boards at each
center review the protocol. It is difficult
to move quickly into an area as
the outbreak occurs and to be ready to
enroll patients before the outbreak is
over. This creates difficulties for
anyone trying to do rigorous studies
on these emerging diseases. Efforts to
respond to, or treat, bioterrorismrelated
events' diseases would likely
be hampered by similar constraints."
The nationwide trial can enroll up
to 110 patients 18 years and older
who have WNV-related encephalitis
or who are at risk of developing the
complication. Trial participants will
receive a single dose of the Israeli
IVIG compound or a dose of one of
The study represents collaboration
among NIAID's Division of
Microbiology and Infectious
Diseases; the NIAID-funded Viral
Studies Group; and the Clinical
Center's Critical Care Medicine
For more information about the trial
visit the NIAID Collaborative
Antiviral Study Group, University
of Alabama, Birmingham website at:
www.casg.uab.edu or www.clinicaltrials.
For information about participating
at the Clinical Center site
call 1-800-411-1222; TTY 1-866-411-
1010. "IVIG - West Nile encephalitis:
Safety and Efficacy" is the formal
name of the trial.
- by Dianne Needham
Pain and Palliative Care Service accredited by ABHPM
The Clinical Center’s Pain and
Palliative Care Service has
just joined an exclusive group
of pain facilities accredited by the
American Board of Hospice and
Palliative Medicine (ABHPM). It is
one of only nine in the United States
to have attained such a distinction.
From left to right: Andrew Mannes, Jacques Bolle, Diane St.
Germain, Donna Pereira, Ann Berger, Eva Cummings, Daniel
Handel, Wendy Wiser, Marcus Walker, Karen Baker and Chad
Based in Glenview, Ill., ABHPM
was formed in 1995 to establish and
implement standards for the certification
of physicians practicing hospice
and palliative medicine.
“ABHPM creates and administers
the certifying examination, works to
implement high standards for training,
and contributes to setting the
standards for excellence in palliative
medicine,” said Dr. Ann Berger, chief
of the service. “So we’re thrilled to
be part of such a small group to have
must arrange for
fellows to care for
patients in inpatient
also are part of
the training experience.
to be one of the
first nine accredited
programs in the country,”
said Dr. Daniel Handel, director of
the fellowship. “Our growing medical
specialty, devoted to symptom management
in incurable and terminal illnesses,
coupled with a holistic,
patient and family centered approach,
relies upon a specific body of knowledge
that is both scientific and experiential
in nature, which is taught
through our interdisciplinary team.”
Getting the accreditation was more
than a mere formality. The requirements
led many of the staff through
training they’d never before received.
“The accredited training programs
are the training ground for the next
generation of physician leaders in
palliative care,” said Dr. Steven
Radwany, PMRC chairman.
“Fellows in these programs learn to
work in interdisciplinary teams and to
value the contributions of other disciplines,
to focus on relieving the suffering
of both patient and family
members, to respond to the physical,
emotional, and spiritual dimensions
of life-threatening illness, to communicate
effectively and compassionately
about very difficult issues with
patients from many cultural backgrounds,
and to help families and
health care teams deal with ethically
These are all skills that are too
often neglected during earlier phases
of a physician’s education, Radwany
added. “Graduates of these newly
accredited training programs will go
out into the community and help their
colleagues with challenging palliative
Other ABHPM members include
Beth Israel Medical Center, New
York City; Cleveland Clinic Harry R.
Horvitz Center for Palliative
Medicine; Marshfield Clinic/St.
Joseph’s Hospital, Ministry Health
Care, Marshfield, Wis.;
Massachusetts General Hospital,
Boston, Mass.; San Diego Hospice
and Palliative Care, San Diego,
Calif.; University of Pittsburgh,
Pittsburgh, Penn.; UT MD Anderson
Cancer Center, Houston, Texas.; and
VA Palo Alto Health Care Service
and Stanford University School of
Medicine, Palo Alto, Calif.
Inhaled nitrite may help babies suffering in a low-oxygen state
Inhaling a simple nitrite spray may
help babies diagnosed with persistent
pulmonary hypertension of the
newborn (PPHN), according to a joint
study conducted by scientists at the
Clinical Center and Loma Linda
University School of Medicine (Loma
Linda, Calif.). Premature newborns
and those with pneumonia or heart
problems often develop PPHN. This
often-fatal disease causes high blood
pressure in an infant's lungs and places
the baby in a low-oxygen state.
The collaborative study findings are
reported in Nature Medicine
(September 12 online version; October,
Nitrite, a simple salt in the blood
that dilates the blood vessels in the
lungs, reacts with de-oxygenated
hemoglobin (respiratory protein of the
blood) and converts to nitric oxide
when the human body is in a lowoxygen
state. Nitric oxide, a shortlived
gas produced by cells lining the
blood vessels, plays an important role
in regulating blood flow. The
NIH-Loma Linda research team theorized
that the naturally occurring conversion
of nitrite to nitric oxide might
help babies with high blood pressure
in the lungs. They correctly predicted
the nitrite conversion mechanism
would lower lung blood pressure and
raise oxygen levels.
The NIH-Loma Linda team studied
the effect of nitrite inhalation in an
animal model of PPHN. They compared
the administration of nitric oxide
with the administration of plain nitrite.
"Nitrite inhalation rapidly reduced
pulmonary pressures by 65 percent,"
said Dr. Christian Hunter, a fellow in
the NIH Clinical Research Training
Program for Medical and Dental students,
a fourth-year Loma Linda medical
student and lead author of the
study. "The nitrite had a much longer
effect than the nitric oxide. In one
case, we administered the inhaled
nitrite for 20 minutes and the high
blood pressure levels were reversed
for an hour."
Delivering nitrite mixed with plain
saline through a plastic inhaler holds
great potential for becoming a much
simpler and more economical way to
treat newborns, according to principal
investigator Dr. Mark Gladwin,
Critical Care Medicine Department,
Clinical Center. "The current clinical
standard for treating these infants is to
administer nitric oxide gas every day
through a complex delivery system
requiring high-level monitoring not
available in small community hospitals
or developing countries," he said.
"This approach costs thousands of dollars
a day and the delivery systems run
tens of thousands of dollars. Our findings
demonstrate this has potential to
be done in an easier and more costeffective
"This research shows that a
common agent found in nature can
have profound health benefits worldwide,"
said Dr. John I. Gallin, Clinical
Center director. "It emphasizes the
importance of persistent, ongoing
clinical research to life and health."
Nitrite also is available for human
use as an antidote for cyanide poisoning
and is used in meat curing, as
Further research is necessary to
determine the safety and efficacy of
inhaled nitrite for human use. Plans
are under way to begin clinical trials
by early 2005. Scientists from NHLBI
and NIDDK at NIH, and from the
Center for Perinatal Biology and
Division of Neonatology, Loma Linda
University School of Medicine, also
participated in this study.
The full text of the study report
may be found in Nature Medicine
online at: http://www.nature.com/cgitaf/
- by Dianne Needham
A Sound of Thanks
During one of his
Baptiste of Point of
Spain, Trinidad and
Tobago, began feeling
ill. Tired all the time, he
was routinely waking up
with a mouth full of
blood, a headache and dizziness.
The family doctor and a specialist
confirmed a diagnosis of severe
aplastic anemia, an acquired bone
marrow disease. His physicians
referred him to the Clinical Center
for further evaluation.
Deon and Ian Baptiste
By November 2003 doctors realized
the only way to help Ian was to
perform a peripheral blood stem cell
transplant. Fortunately, his brother
Deon was the willing-and best
suited-donor because he is Ian's
"When I heard how sick Ian was I
started crying. I wanted to help. I
didn't need an explanation. I just
wanted to get it done," said Deon.
"Ian is my brother, my buddy."
A peripheral blood stem cell transplant
was performed on Christmas
Eve 2003. Slowly Ian's health
improved. One year to the day from
when Ian first came to the Clinical
Center, he and Deon gave NIH a very
The twins' passion is music and
dance. They perform with Jeunes
Agape ("young unconditional love"),
a Point Fortin, Trinidad and Tobagobased
musical-drama group. On
September 2 Jeunes Agape performed
a memorable concert of uplifting
music, song and dance in the Masur
"This was really a morale boost for
us to see that what we do does make
a difference, said Hematology and
Transplant Clinical Nurse Specialist
Nonniekaye Shelburne. "Ian and
Deon gave back to us, too, not just in
research but in friendship."
- by John Iler
Daniels leaves Clinical Center for the
University of California, San Diego
Pharmacy chief Dr. Charles
("Chuck") Daniels left the
Clinical Center in September
to become professor of clinical pharmacology
and associate dean of the
School of Pharmacy and
Pharmaceutical Sciences at the
University of California, San Diego.
He also is pharmacist-in-chief in the
university's health system.
Daniels had been pharmacy chief
at the Clinical Center for nine years.
During that time, he has seen
"growth in patient-oriented pharmacy
services and safety improvements in
the administration of medication in
the Clinical Center" as his greatest
accomplishments. "Collaboration in
pharmacy research also has grown
substantially and has increased the
number of highly qualified staff at all
levels," he said.
Dr. Chuck Daniels
"A number of things are still being
improved, such as the pharmacy's
physical plant, which is in need of
significant upgrades," he added. Both
of these have already been addressed
in the building of the new Clinical
Research Center and future enhancements
in the Magnuson Center.
"The Clinical Center leadership
has provided strong support for highquality
pharmacy services since I
arrived at NIH. Personnel and budgetary
issues always influence how
much can be done and how fast,"
said Daniels. "But I have never had a
good idea rejected outright, even
though some, concerning pharmacy
automation and space, have had to
be placed in queue for practical reasons."
Before coming to the Clinical
Center, Daniels spent 15 years at the
University of Minnesota College of
Pharmacy and University Hospital.
Bob DeChristoforo has been named
acting chief until a Pharmacy
Department chief is selected.
2004 Flu Vaccine Schedule Vaccine Schedule
The flu vaccine clinic is being held on the B1 level of the Clinical Center (Building 10, Visitor Information Center, Little
Theater) to serve NIH employees.
Some things to remember: Do not go to the OMS 6th Floor Clinic. The clinic will administer vaccinations based on
the first letter of the employee's last name. Employees showing up on the wrong day can expect to wait. Wear a
short sleeve shirt or jacket/sweater that can be quickly removed to expose your upper arm. Finally, this program is for
NIH employees only.
EFGH: Monday, Oct. 18 7:30-11:00 1:00-3:30
IJKLM: Tuesday, Oct 19 7:30-11:00 1:00-3:30
NOPQRS: Wednesday, Oct 20 7:30-11:00 1:00-3:30
TUVWXYZ: Thursday, Oct 21 7:30-11:00 1:00-3:30
ABC: Friday, Oct 22 7:30-11:00 1:00-3:30
IJKLM: Monday, Oct 25 7:30-11:00 1:00-3:30
NOPQRS: Tuesday, Oct 26 7:30-11:00 1:00-3:30
TUVWXYZ: Wednesday, Oct 27 7:30-11:00 1:00-3:30
ABCD: Thursday, Oct 28 7:30-11:00 1:00-3:30
EFGH: Friday, Oct 29 7:30-11:00 1:00-3:30
RKL I Rm 5054 Mon./Tues., Nov 1 and 2 8:30-11:00 1:00-3:00
Poolesville Tuesday, Nov 2 8:30-11:00 1:00-3:00
EPN Rm 103 Wed./Thur. Nov 3 & 4 8:30-11:00 1:00-3:00
TW2 Rm 200F Friday, Nov 5 8:30-11:00 1:00-3:00
NSC Conf Rm 3103 Mon./Tues. Nov 8 and 9 8:30-11:00 1:00-3:00
On campus location: Building 10/ Visitor Information Center/Little Theater
Make-up Dates On Campus
Building 10, Room 6C306-OMS Nov. 10,12,15,16,17 7:30-11:00 1:00-3:30
For flu vaccine information, log on to www.nih.gov/od/ors/ds/flu
Medicine for the Public Lectures 2004
Medicine for the
the latest developments
working in the frontiers
of medical discovery at
NIH relate stories of science to the lay public.
The lecture series, now in its 28th year, will
cover the following topics for the 2004
Dietary Supplements: What Do You Know?
What Should You Know?
Dr. Paul M. Coates, director, Office of Dietary
Supplements, National Institutes of Health
Through the Looking Glass: The Future of
Medicine and the Building of the Mark O.
Hatfield Clinical Research Center
Dr. John I. Gallin, director, Clinical Center,
National Institutes of Health
Dr. Robert Frasca, partner-in-charge of
design, Zimmer Gunsul Frasca Partnership
Evidence-Based Education: Preventing
Reading Failure in America
Dr. G. Reid Lyon, research psychologist and
chief, Child Development and Behavioral
Branch, Center for Research for Mothers and
Children, National Institute
The Biomechanics of Human Movement:
Could Leonardo da Vinci Fly?
Dr. Steven Stanhope, director, Physical
Disabilities Branch, Rehabilitation Medicine
Department, NIH Clinical Center and National
Institute of Child Health and Human
Addiction to Medications: What Are the
Risks and Who Is Vulnerable?
Dr. Nora D. Volkow, director, National Institute
on Drug Abuse
Viruses, Vaccines and Emerging Health
Dr. Gary J. Nabel, director, Vaccine Research
Center, National Institute of Allergy and
Lectures are held Tuesdays at 7 p.m. in the
Clinical Center's Masur Auditorium and are
free and open to the public. For more information,
call 301-496-2563 or visit http://clinicalcenter.nih.gov/about/news/mfp.shtml.
Goldstein is 2004 Distinguished
NINDS researcher Dr.
David Goldstein was
recently named the 2004
Distinguished Clinical Teacher.
He was recognized as an exemplary
clinical mentor and outstanding
teacher who played an
important role in the professional
development of clinical fellows.
Dr. John Gallin (left) and Dr. Melinda Merchant present Dr. Goldstein with his award
"The DCT award is given to
an NIH faculty member who
exemplifies the ideal of a
mentor, teacher, clinician, and
researcher," said Dr. Melinda
Merchant, senior clinical fellow in
the Pediatric Oncology Branch, NCI,
and Felcom subcommittee chairman
for the award. "The award is given by
the fellows to a role model of the
clinical teacher they one day would
like to become." The 2004 DCTA
winner, she added, is "indeed a fantastic
role model and exemplary
Goldstein is chief of the Clinical
Neurocardiology Section, Clinical
Neuroscience Program, NINDS. He
has conducted pioneering research on
the autonomic nervous system and is
the author of hundreds of papers on
the topic. He has an international
research reputation and has been
awarded the NIH Merit Award and
the Laufberger Medal of the Czech
Academy of Sciences.
"There has never been a time when
I could not contact him or sit and ask
him questions of him, even when he
has been very busy," said one fellow.
"He creates a working environment
in which he leads by consensus. This
quality makes him a true mentor."
For all his accomplishments, the
2004 Distinguished Clinical Teacher
winner has not lost the personal touch
with either his patients or with those
he mentored. "He excels in all the
criteria that were listed as a mentor,"
said one, "and with all my heart I
confirm each and every one of them.
He has touched lives including
October Grand Rounds, Events
Oct. 6: Wednesday, 12 noon - 1 p.m., Grand Rounds for Fellows
How Far Away Is the Future for Patients with Lupus?
Dr. Bevra H. Hahn, professor of Medicine, Department of Rheumatology, David Geffen School
of Medicine, UCLA
Oct 13: 12 noon - 1 p.m. - Contemporary Clinical Medicine: Great Teachers
IL-1 and IL-18 as Targets of Inflammatory Diseases
Dr. Charles Dinarello, professor of Medicine, University of Colorado School of Medicine
Oct 20: 12 noon - 1 p.m.- 4th Annual John Doppman Memorial Lecture for Imaging Sciences
Molecular Genetic Reporter Strategies for Imaging Protein Function and Protein-Protein
Interactions in Living Animals
Dr. David Piwnica-Worms, professor of Radiology and professor of Molecular Biology &
Pharmacology, director, Molecular Imaging Center, Washington University School of Medicine
Oct 26: 12 noon - 1 p.m. - NCCAM Lecture
Reverse Herbology: Predicting and Preventing Adverse Herb-Drug Interactions,
Dr. Steven A. Kliewer, professor Molecular Biology and Pharmacology
Nancy B. and Jake L. Hamon Distinguished Chair in Basic Cancer Research
University of Texas Southwestern Medical Center, Dallas.
Oct 27: 12 noon - 1 p.m.-Ethics Rounds,
The Ethics of Altruistic Organ Donation, Dr. Baruch Brody, director, Center for Ethics and
Public Health, Baylor College of Medicine
Lectures can be accessed on the NIH videocast at http://videocast.nih.gov
writers: Dr. John Gallin, Dianne Needham, Colleen Henrichsen, John Iler, Pat McNees
Clinical Center News, National Institutes of Health, 6100 Executive Blvd., Suite 3C01, Bethesda, MD 20892-7511. Tel: 301-496-2563.
Fax: 301-402-2984. Published monthly for CC employees by the Office of Clinical Center Communications, Colleen Henrichsen, chief. News,
article ideas, calendar events, letters, and photographs are welcome.